Alain Zeitoun - Purple Biotech External Director
| KTOV Stock | ILA 20.00 0.20 1.01% |
Director
Dr. Alain Zeitoun serves as External Director at Kitov Pharmaceuticals Holdings Ltd since December 16, 2013. His work experience includes the role of Chief Executive Officer and Business Consultant at Chi2Gel Ltd. for six years and Independent Consultant for medical devices, biotechnology and pharma sector for seven years. He holds a Doctorate of Medicine degree in Medicine from ESCP Paris Business School and a Masters degree in Management from Paris XIII University. since 2013.
| Age | 54 |
| Tenure | 11 years |
| Phone | 972 3 933 3121 |
| Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michal Preminger | Compugen | N/A | |
| Ruth Arnon | Compugen | 86 | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Rachel Ari | Bonus Biogroup | 55 | |
| Sanford Zweifach | Compugen | 60 | |
| Dov Hershberg | Compugen | 74 | |
| Kinneret Savitsky | Compugen | 50 | |
| Yair Aharonowitz | Compugen | 73 | |
| Gil Shapira | Bonus Biogroup | 56 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Gilead Halevy | Compugen | 51 | |
| Arie Ovadia | Compugen | 67 | |
| Avi Slonim | Bonus Biogroup | 38 | |
| Batia Avital | Bonus Biogroup | 54 | |
| Joshua Shemer | Compugen | 63 | |
| Eran Perry | Compugen | N/A | |
Management Performance
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itzhak Israel, Chief Executive Officer & Director | ||
| Steven Steinberg, Independent Director | ||
| Gil BenMenachem, Vice President - Business Development | ||
| Michael Schickler, Head of Clinical Operations | ||
| Philip Serlin, Independent Director | ||
| CPA MBA, Strategic Director | ||
| Arie Weber, Independent Director | ||
| Bertrand Liang, Chief Medical Officer | ||
| Yisrael Gewirtz, Internal Auditor | ||
| John Waymack, Chairman of the Board & Chief Medical Officer | ||
| Ran Tzror, Independent Director | ||
| Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
| Simcha Rock, CFO, Director | ||
| Eric Rowinsky, Chairman of the Board | ||
| Moran SherfBlau, External Director | ||
| Ido Agmon, Independent Director | ||
| Gil CPA, Deputy CFO | ||
| Leah Bruck, Director | ||
| Isaac Israel, CEO Director | ||
| Revital SternRaff, Independent Director | ||
| Pinhas BarShmuel, Internal Auditor | ||
| Avraham BenTzvi, General Counsel, Secretary | ||
| Alain Zeitoun, External Director | ||
| Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 | |||
| Operating Margin | (7.54) % | |||
| Shares Outstanding | 172.11 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.22 % | |||
| Price To Earning | (364.21) X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 16.36 X | |||
| Revenue | 1000 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Purple Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Purple Biotech's short interest history, or implied volatility extrapolated from Purple Biotech options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |